Business Wire

MT-UAVIONIX

24.3.2021 23:10:12 CET | Business Wire | Press release

Share
uAvionix Receives DoD AIMS Certification for Mode 5 Micro IFF Transponder for Tactical UAS

uAvionix Corporation today announced it achieved DoD AIMS Mk XIIB certification of its first Identification Friend or Foe (IFF) transponder, the RT-2087/ZPX-B . With this certification, ZPX-B becomes the world’s smallest, certified micro-IFF transponder, reducing Size, Weight, and Power Consumption (SWaP) characteristics of typical IFF transponders by more than 90%, and at less than half the size, one-third the weight, and one fourth the power consumption of other Unmanned Aircraft Systems (UAS) targeted IFF solutions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005976/en/

The certification, issued by the Department of Defense (DoD) Air Traffic Control Radar Beacon System Identification Friend or Foe Program Office (AIMS PO), attests to its IFF capability and its interoperability with military equipment fielded by NATO and its allied countries. Incorporation of IFF technology into small, tactical, and attritable platforms allows them full participation into the cross-troop, cross-service branch, and cross-nation collaboration and situational awareness that prevents fratricide.

The ZPX-B enables IFF capability for small and tactical Group 1-4 UAS, thanks to its record-breaking SWaP at 3.3 in3 , 60 grams, and power consumption of only 3.5 Watts. Transmitting at 54dBm, ZPX-B provides civil transponder modes A, C, S, and ADS-B Out, as well as military modes 1, 2, 3, and 5 Levels 1 and 2 – all individually configurable. ADS-B In functionality provides situational awareness and Detect and Avoid (DAA) capabilities to the host platform. Crypto compatibility complies with AIMS 04-900A Option B, which includes the KIV-77 and KIV-79.

Passive IFF Reception for Situational Awareness

In addition to the ZPX-B, uAvionix introduces the ZPX-R, a passive ADS-B and Mode 5 Level 2 receiver for ground-based, shipborne, or airborne reception for situational awareness and DAA capability. Mode 5 Level 2 encrypted squitters enable situational awareness in areas where Mode 5 interrogators are absent, increasing the scalability of deployment. ZPX-R can provide data in multiple formats, including Open Mission Systems (OMS) for incorporation into tactical displays or ACAS Xu or similar DAA processors.

Unclassified Integration, Testing, and Demonstration with Crypto Emulation

For military programs or OEMs looking to integrate a micro-IFF into their platforms, ZPX-B incorporates an internal crypto-emulator that enables development and test independent of COMSEC-controlled equipment subject to onerous handling requirements.

For more information on the uAvionix line of defense products, including IFF transponders, receivers, GPS, and crypto emulators, visit https://uavionix.com/defense/ .

Link:

ClickThru

Social Media:

https://www.facebook.com/uavionix

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

DCX builds coolant chemistry control into its 8 MW Facility Distribution Unit19.10.2026 14:01:00 CEST | Press release

DCX introduces groundbreaking new safety standard protecting critical AI infrastructure by monitoring and keeping the entire coolant loop Continuous monitoring of eight coolant parameters and automatic dosing keep hall-scale liquid-cooling loops in specification between service visits Today DCX Liquid Cooling Systems announced worldwide’s first CDU system with built-in coolant control and treatment system. DCX integrated this coolant quality feature into it’s Facility Coolant Distribution Units: a family of 5-8 MW capable hyperscale-class coolant Distribution Units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014488003/en/ DCX announces the world’s first CDU with built-in coolant quality control and treatment - a new safety standard for hall-scale Liquid Cooling in critical AI infrastructure. The FDU monitors the chemistry of its coolant continuously and corrects it automatically with integrated electronic dosing pumps

STARTEEPO Sends Letter to Xerox Board in Advance of Third-Quarter Earnings19.10.2026 14:00:00 CEST | Press release

Company’s Third Largest Shareholder Expects Update on Increased Transparency, Strategic Review of Xerox Financial Services Business Unit, and Continued DeleveragingSTARTEEPO Chairman František Bostl to Address Xerox Investment at Skytop Conference in London STARTEEPO SICAV a.s. (“STARTEEPO”), which beneficially owns 7.34% of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX) in stocks and options, today issued the following letter to the Xerox Board of Directors (the “Board”): October 19, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Our open letter to the Board in early September helped spark a lively conversation about the future of this iconic company among investors and throughout the print industry. Despite these efforts, Xerox’s share price still does not reflect the significant value we see in the Company, a gap recently confirmed by Citi’s downgrade of Xerox stock to reflect the challenge of executin

The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Expertsin Vienna19.10.2026 12:00:00 CEST | Press release

Data Center World Europe 2027 took place October 13-15 at VIECON – Vienna Congress & Convention Center in Austria Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 12:00:00 CEST | Press release

New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and brain-penetrant PRMT5 inhibitor underscore the depth of BeOne’s solid tumor pipelineMultiple TEVIMBRA abstracts reinforce breadth of evidence across lung and gastrointestinal cancers, including data in combination with ZIIHERA in HER2+ gastroesophageal cancer BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 11:30:00 CEST | Press release

More than half of ENTYVIO patients who met their assigned treatment target reached disease clearance (composite of corticosteroid-free symptomatic, endoscopic and histologic remission) at Week 16VERDICT is the first trial to provide macroscopic and microscopic evidence of intestinal tissue repair associated with disease clearance in largely bio-naïve patients treated with an advanced therapy​ Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically rel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye